Molecular Profiling of Aromatase Inhibitor Sensitive and Resistant ER+HER2- Postmenopausal Breast Cancers

Given the limited understanding of intrinsic resistance in estrogen receptor positive (ER+) breast cancer (BC) tumors, scientists conducted a large-scale molecular analysis to identify features that impacted the response of ER + HER2- BC to aromatase inhibitors.